Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jun 11, 2014

166_ip_2014-06-11_dc4c6c8a-9270-460d-8c65-532a2a150a1c.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

A Leading Global Health Care Group

Deutsche Bank ‒ dbAccess German, Swiss & Austrian Conference June 11, 2014

For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Strong and Balanced Health Care Portfolio

Dialysis products and services

Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77%

Hospital supply Hospital operations Hospital projects and services

2
0
1
3
G
N
I
C
i
b
i
t
t
t
r
o
u
p
e
n
c
o
m
e
o
n
r
u
o
n
2
5
%		 6
%
4		 2
6
%		 3
%

Favorable Industry Dynamics

Aging population and higher incidence of chronic diseases

World population age 60+ will more than double by 2050 to >2 bn (OECD)

Increasing health care spending in emerging markets

Increasing health care coverage and per capita spending (e.g. India: US\$59, China: US\$278, vs. USA: US\$8,608; WHO)

Continuing growth of generics

Approx. US\$19 bn branded IV drug sales (base: 2013) go off-patent in the U.S. by 2023

Rise of private providers in health care services

Further privatization of German hospital market Global opportunity to provide dialysis services (e.g. China, India)

Fresenius Group 2013: New Sales and Earnings Records – >1€ bn Net Income One Year Ahead of Plan

Before special items

Q1/2014 Financial Results

S
l
a
e
s		 1
E
B
I
T		 1
i
N
t
e
n
c
o
m
e
€
5
2
1
2
m
,		 €
6
4
3
m		 €
2
2
8
m
h
G
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 1
1
%		 6
%
-		 3
%
G
h
l
t
t
t
r
o
w
a
a
c
u
a
t
e
n
e
c
u
r
r
c
y
r
a
s		 7
%		 8
%
-		 2
%

1Before special items

Q1/2014 Financial Results by Business Segment

Q
/
1
1
4		 i
F
r
e
s
e
n
s
u
M
d
i
l
C
e
c
a
a
r
e		 i
F
r
e
s
e
n
s
u
K
b
i
a		 i
F
r
e
s
e
n
s
u
H
l
i
e
o
s		 i
F
r
e
s
e
n
s
u
V
d
a
m
e
l
S
a
e
s
G
h
t
o
r
w		 \$
U
S
3
5
6
4
m
,
3
%		 €
1
2
1
3
m
,
%
4
-		 €
1
2
2
7
m
,
6
%
4		 €
1
9
1
m
%
4
E
B
I
T
h
G
t
o
r
w		 \$
U
S
4
4
5
m
1
0
%
-		 €
2
0
1
m
1
%
5
-		 €
1
1
4
m
3
1
%		 €
6
m
2
0
%

Q1/2014 Business Update

Operations & Markets

Europe

  • 2% organic sales decline, mainly due to (i) reduced HES sales and (ii) changes in Russian distribution model
  • Confirm 2% 5% 2014e organic sales growth

Asia-Pacific

  • 3% organic sales growth (10% excluding China) reflecting (i) yoy price cut impact, (ii) discontinuation of HES200 solution in China and (iii) delayed tenders in Australia and Vietnam
  • Confirm >10% 2014e organic sales growth

HES blood volume replacement

~€20 m sales decline yoy; €4 m sequential reduction

Q1 Business Update

Operations & Markets

h
N
A
i
t
o
m
e
c
a
r
r
l
l
h
h
f
l
d
Q
/
3
F
t
i
t
t
i
t
1
1
a
o
r
g
a
n
c
s
a
e
s
g
r
o
w
o
n
s
o
r
a
g
e-
n
a
e
-
-2
%
%
2
0
1
i
l
h
N
E
W
t
5
4
t
+
:
o
e
o
r
g
a
n
c
s
a
e
s
g
r
o
w
-
(
i
l
%
%
)
-5
t
5
+
p
r
e
v
o
u
s
y
:
o
h
d
h
l
d
l
d
1
D
S
i
C
i
0.
9
%
i
i
t
t
t
r
u
g
s
o
r
a
g
e
o
u
m
o
r
e
r
e
g
u
a
o
r
y
s
c
r
e
o
n
–
-
f
f
d
d
l
i
i
E
i
D
3
1,
2
0
1
4
t
t
t
t
o
m
p
o
o
n
o
m
o
p
e
e
e
n
e
n
e
r
r
a
r
u
r
x
u
c.
l
f
l
l
f
d
F
D
A
i
P
R
i
i
t
t
t
t
t
a
n
n
g
e
e
o
e
o
c
o
p
a
n
e
w
r
r
r
u
r
-
f
h
l
k
h
l
A
i
i
i
R
ö
K
i
i
i
t
t
c
q
s
o
n
o
n
n
m
o
s
p
a
s
u
u
-
d
E
P
S
i
i
Q
1,
i
i
t
t
t
t
t
a
c
c
e
e
n
n
o
n
e
g
a
o
n
c
o
s
o
c
c
e
e
r
v
r
u
r
r
y
-
l
l
d
f
2
0
E
t
H
S
K
i
t
t
J
1
4
p
e
c
c
o
s
n
g
a
e
s
e
n
o
n
e
x
u
-
i
d
2
0
i
d
f
l
l
h
i
l
(
i
l.
S
)
i
h
P
1
4
t
H
K
t
r
o
v
e
g
u
a
n
c
e
o
r
a
o
s
p
a
s
n
c
w
-
Q
2
l
d
f
l
t
J
r
e
s
u
s
e
n
o
u
y		 Maxim
e hosp
itals
um car
are ho
spitals
Acute c
Acute c
are hos
pitals/
e clinic
post-ac
ute car
s
Post-ac
ute car
e clinic
s
al of m
l
Approv
unicipa
shareh
olders
pendin
g
Compa
ny hea
dquart
ers

1FDA may reconsider the discretion before the end of the year, if the shortage has been alleviated.

Q1 Business Update

Operations & Markets

Strong start into the year

€115 m order entry in Q1 – driven by hospital projects in emerging markets

Strategic Initiatives

Emerging markets expansion

  • Promising acquisition pipeline to expand presence in fastgrowing markets
  • Currently pursuing only small and midsize transactions

Fresenius Group: Financial Outlook by Business Segment Fully Confirmed / Narrowed

O
l
d		 N
e
w
F
i
r
e
s
e
n
u
s
K
b
i
a		 l
h
S
t
i
a
e
s
g
o
r
w
o
r
g
a
n
c
E
B
I
T
i
m
a
r
g
n		 3
%
7
%
–
6
%
8
%
1
1
–		 4
%
6
%
–
6
%
8
%
1
5
1
–
i
F
r
e
s
e
n
u
s
1
H
l
i
e
o
s		 l
h
S
t
i
a
e
s
g
o
r
w
o
g
n
r
a
c
E
B
I
T		 3
%
5
%
–
€
3
9
0
€
0
4
1
m
–
i
F
r
e
s
e
n
u
s
V
d
a
m
e		 l
h
S
t
i
a
e
s
g
o
r
w
o
g
n
r
a
c
h
E
B
I
T
t
g
r
o
w		 5
%
1
0
%
–
%
0
%
5
1
–

1 Excl. acquired Rhön hospitals; before integration costs for acquired hospitals net of book gain from the divestment of two HELIOS hospitals

Fresenius Group: Financial Outlook Fully Confirmed

1
G
d
i
2
0
1
4
u
a
n
c
e
h
R
t
e
e
n
e
g
o
v
u
r
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 2
%
%
1
1
5
‒
2
h
N
i
t
t
e
n
c
o
m
e
g
o
r
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
%
%
5
‒

1Guidance includes acquired Rhön hospitals

2 Net income attributable to shareholders of Fresenius SE& Co.KGaA before integration costs for Fenwal (€30-40 million after tax) and for the hospitals acquired from Rhön-Klinikum AG, net of book gain from the divestment of two HELIOS hospitals (€21 million after tax)

Fresenius Group: Attractive Mid-Term Growth Prospects

Strong and Balanced Health Care Portfolio

Attachments

Fresenius Group: Profit and Loss Statement

/
/
Q
Q
3
1
1
4
1
1		 /
G
h
Q
Y
Y
t
1
1
4
r
o
w
o
l
t
a
c
a
u
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
5
2
1
2
,		 4
8
9
0
,		 7
%		 1
1
%
6
3
4		 6
9
6		 8
%
-		 6
%
-
8
1
3
-		 1
6
3
-		 1
5
%		 1
3
%
3
3
1
-		 1
5
5
-		 %
1
4		 0
%
1
2
2
8		 2
2
4		 2
%		 3
%

1 2014 before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million); 2013 before Fenwal integration costs (€7 million) Net income attributable to shareholders of Fresenius SE & Co. KGaA, before Fenwal integration costs (€1 million) and the book gain from the divestment of two HELIOS hospitals (€21 million); 2013 before Fenwal integration costs (€5 million)

Fresenius Kabi: Organic Sales Growth in Line with Expectations

€
m		 /
Q
1
1
4		 /
Q
1
1
3		 O
i
r
g
a
n
c
G
h
t
r
o
w
f
h
I
i
T
n
s
o
n
e
a
p
u
r
y		 2
3
0		 2
5
0		 1
%
-
I.
V
D
g
s
r
u		 1
4
4		 6
0
4		 0
%
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 3
1
8		 3
2
6		 2
%
d
l
/
M
i
D
i
e
c
a
e
v
c
e
s
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 2
2
4		 2
2
4		 3
%
l
l
T
t
o
a
s
a
e
s		 1
2
1
3
,		 1
2
6
0
,		 %
1

Fresenius Kabi: Organic Sales Growth in Line with Expectations

€
m		 /
Q
1
1
4		 /
Q
1
1
3		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
u
r
o
p
e		 0
0
5		 5
1
7		 2
%
-
h
N
A
i
t
o
m
e
c
a
r
r		 3
8
2		 0
4
1		 0
%
f
A
i
P
i
i
s
a
a
c
c
-		 2
2
2		 2
2
3		 3
%
/
f
L
i
A
i
A
i
t
a
n
m
e
r
c
a
r
c
a		 1
0
9		 1
1
9		 1
1
%
l
l
T
t
o
a
s
a
e
s		 1
2
1
3
,		 1
2
6
0
,		 %
1

Fresenius Kabi: EBIT Margin Fully in Line with Guidance

€
m		 /
Q
1
1
4		 /
Q
3
1
1		 G
h
t
r
o
w
E
u
r
o
p
e
M
i
a
r
g
n		 9
6
3.
8
%
1		 8
4
6.
2
%
1		 8
1
%
-
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
r
g
n		 1
4
7
3
8.
%
5		 1
5
4
3
8.
%
4		 %
5
-
f
/
/
f
A
i
P
i
i
L
i
A
i
A
i
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
M
i
a
g
n
r		 4
9
1
4
8
%		 6
5
1
9
0
%		 2
5
%
-
d
C
C
&
t
t
R
D
o
p
o
a
e
a
n
o
p
o
a
e
r
r
r
r		 6
4
-		 6
6
-		 %
3
l
T
E
B
I
T
t
o
a
M
i
a
r
g
n		 2
0
1
%
1
6
6		 2
3
7
%
1
8
8		 %
1
5
-

EBIT excluding Fenwal integration costs (€1 million)

Fresenius Helios: Organic Sales Growth in Line with Expectations

€
m		 Q
/
1
1
4		 Q
/
1
1
3		 G
h
t
r
o
w
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
o
o
r		 8
5
7		 8
2
6		 4
%
A
i
i
i
t
c
q
s
o
n
s
(
l
i
d
i
1
)
u
t
<
c
o
n
s
o
a
o
n
y
r		 3
7
0
D
i
i
t
t
(
d
l
d
)
v
e
s
u
r
e
s
i
i
1
t
<
e
c
o
n
s
o
a
o
n
y
r		 1
5
T
l
l
t
o
a
s
a
e
s		 1
2
2
7
,		 8
4
1		 4
6
%

Fresenius Helios: Sales and EBIT Growth Driven by First-Time Consolidation of Rhön Hospitals

€
m		 Q
/
1
1
4		 Q
/
1
1
3		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 2
2
1
7
,		 8
4
1		 %
4
6
E
B
I
T
b
l
h
d
l
f
l
E
i
i
i
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
i
M
a
r
g
n		 8
8
1
0.
3
%		 8
5
1
0.
3
%		 %
4
/
A
i
i
i
D
i
i
t
t
t
c
q
u
s
o
n
s
v
e
s
u
r
e
s
(
l
d
/
d
l
d
)
i
t
i
i
t
i
1
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 2
6		 2
T
l
E
B
I
T
t
o
a		 1
1
4		 8
7		 3
%
1
M
i
a
r
g
n		 %
9
3		 %
1
0
3

EBIT excluding book gain from the divestment of two HELIOS hospitals (€22 million)

Fresenius Helios: Performance Indicators

Q
/
1
1
4		 Q
/
1
1
3		 C
h
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
i
i
t-
t
o
s
a
c
e
c
a
e
c
n
c
s
u
r
-		 1
0
9
8
5
2
4		 7
4
5
1
2
3		 4
7
%
6
%
7
4
%
1
f
b
d
N
o
o
e
s
l
i
i
A
t
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 3
3
0
0
9
,
2
9
0
0
7,
0
9
5,
1		 2
3
5
0
2
,
8,
8
8
1
5
6
4,
1
7		 4
0
%
8
%
4
%
1
1
d
A
i
i
m
s
s
o
n
s
A
(
i
i
)
t
t
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 2
7
6,
6
0
0		 1
9
6,
1
0
7		 4
1
%
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 7
9
%		 7
9
%
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
6
2
7.
1		 6.
6
2
7.
6

1December 31, 2013

Deutsche Bank ‒ dbAccess German, Swiss & Austrian Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 11, 2014

Fresenius Helios: 2013 Clinic Development Plan

Y
i
P
f
l
i
t
e
a
r
s
n
o
r
o
o
1
<		 1 2 3 4 5 6 6
>		 T
l
t
o
a
f
l
N
i
i
o.
o
c
n
c
s		 - 2
1		 3 1 - 6 4 8
4		 7
4
(
€
)
R
e
v
e
n
u
e
m		 - 3
9
0		 1
5
5		 3
8		 - 9
6
1		 3
2
1		 2,
9
8
1		 3,
2
8
9
T
t
a
r
g
e
i
(
%
)
E
B
I
T
m
a
r
g
n		 - 2.
0		 0
4		 6.
0		 8.
0		 1
0.
0		 1
2.
0		 1
2.
0-
1
0
5.
(
)
E
B
I
T
€
m		 - 7.
8		 6.
2		 2.
3		 - 1
9
6		 3
7.
4		 2
6
3.
8		 3
3
7.
1
R
d
t
e
p
o
r
e
(
%
)
E
B
I
T
i
m
a
r
g
n		 - 1
1.
4		 0.
5		 3.
4		 - 7.
5		 2.
8
1		 3.
0
1		 8
1
1.
(
€
)
E
B
I
T
m		 - 6
4
4		 0.
8		 3
1.		 - 1
4
7		 3
9
9		 2
8
9
5.		 3
8
2
7.
f
l
i
i
N
t
t
>
o.
o
c
n
c
s
a
r
g
e		 - 9 1 - - 2 2 1
7		 3
1
f
l
i
i
N
t
t
<
o.
o
c
n
c
s
a
r
g
e
IFR
S		 - 3 2 1 - 4 2 3
1		 3
4

Deutsche Bank ‒ dbAccess German, Swiss & Austrian Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 11, 2014

Fresenius Vamed: Excellent Sales and EBIT Growth

€
m		 /
Q
1
1
4		 /
Q
3
1
1		 G
h
t
r
o
w
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s		 8
0		 8
2		 2
%
-
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 1
1
1		 1
0
2		 9
%
T
l
l
t
o
a
s
a
e
s		 9
1
1		 8
1
4		 %
4
T
l
E
B
I
T
t
o
a		 6 5 %
2
0
M
i
a
r
g
n		 3
%
1		 2
%
7
1
O
d
i
k
t
r
e
r
n
a
e		 1
1
5		 9
3		 %
2
4
1
O
d
b
k
l
r
e
r
a
c
o
g		 1
1
7
0
,		 2
1
1
3
9
,		 %
3

Project business only

2December 31, 2013

Consistent Cash Generation and Proven Track Record of Deleveraging

Cash Flow Development

€
m		 C
O
i
F
t
p
e
r
a
n
g		 (
)
C
t
a
p
e
x
n
e		 1
C
F
h
F
l
r
e
e
a
s
o
w
/
Q
1
1
4		 L
T
M
M
i
a
r
g
n		 /
Q
1
1
4		 L
T
M
M
i
a
r
g
n		 /
Q
1
1
4		 L
T
M
M
i
a
r
g
n
2
4		 8
0
%		 6
5
-		 6
%
4
-		 2
3
-		 1
6
%
7
7		 8
0
%		 3
1
-		 %
4
7
-		 6
4		 3
3
3
%
5
4
-		 6
6
%
-		 1
-		 1
1
%
-		 5
5
-		 7
7
%
-
Co
/
te
rp
or
a
O
he
t
r		 7
-		 %
1
1
1
-		 2
-		 3
6
%
1		 9
-		 2
%
5
l.
F
M
C
ex
c		 5
8		 2
7
3
%		 9
9
-		 5
3
%
-		 4
1
-		 2
2
0
%
Gr
ou
p		 1
4
0		 %
9
8		 2
4
3
-		 %
5
4
-		 1
0
3
-		 %
4
4

1 Before acquisitions and dividends

2 Margin incl. FMC dividend

3 Understated: 4.1% excluding €31 million of capex commitments from acquisitions

Deutsche Bank ‒ dbAccess German, Swiss & Austrian Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 11, 2014

Fresenius Group: Debt and Interest Ratios

12014 before integration costs for Fenwal (€1 million) and the book gain from the divestment of two HELIOS hospitals (€22 million)

2Pro forma acquired hospitals from Rhön-Klinikum

32013 before integration costs for Fenwal (€54 million); debt excluding advances of €2.18 bn for the acquisition of hospitals from Rhön-Klinikum

Deutsche Bank ‒ dbAccess German, Swiss & Austrian Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, June 11, 2014

Share Information

Share key facts

Number of shares1 179,824,079 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Exchange OTCQX International Premier Structure Sponsored Level I ADR

1As of March 31, 2014

Financial Calendar 2014

3
1
0
7
2
0
1
4		 t
h
l
f
R
1
2
0
1
4
t
s
e
p
o
r
o
n
a
0
4
1
1
2
0
1
4		 d
t
R
1
3
2
0
1
4
t
t
s
r
e
p
o
r
o
n
q
u
a
r
e
r
–

Please note that these dates could be subject to modifications.

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.